SCM
BMY.RT

Solas Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Solas Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-900,000
Closed -$621K – 31
2020
Q4 		$621K Hold
900,000
– – 0.47% 28
2020
Q3 		$2.02M Buy
+900,000
New +$2.57M 1.94% 19

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Solas Capital Management's BMY.RT Position: Q1 2021 in Review

Solas Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 900,000 shares — an estimated $621K sold.

Solas Capital Management first reported a position in BMY.RT in Q3 2020 and held it in 2 quarters. The position peaked at $2.02M in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Solas Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Solas Capital Management sold 900,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $621K.
  • Solas Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 2 quarters.
  • Solas Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2.02M in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Solas Capital Management's 13F filing for Q1 2021, filed 17 May 2021.